RU2012124090A - Реагенты и способы для определения клеток ii типа при pnh - Google Patents

Реагенты и способы для определения клеток ii типа при pnh Download PDF

Info

Publication number
RU2012124090A
RU2012124090A RU2012124090/15A RU2012124090A RU2012124090A RU 2012124090 A RU2012124090 A RU 2012124090A RU 2012124090/15 A RU2012124090/15 A RU 2012124090/15A RU 2012124090 A RU2012124090 A RU 2012124090A RU 2012124090 A RU2012124090 A RU 2012124090A
Authority
RU
Russia
Prior art keywords
type
leukocytes
pnh
patient
reagent
Prior art date
Application number
RU2012124090/15A
Other languages
English (en)
Russian (ru)
Inventor
Маюр МОВАЛИА
Андреа ИЛЛИНГВОРТ
МАКНАЙТ Сьюзан ФААС
Расселл П. Ротер
Original Assignee
Алексион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалз, Инк. filed Critical Алексион Фармасьютикалз, Инк.
Publication of RU2012124090A publication Critical patent/RU2012124090A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
RU2012124090/15A 2009-11-09 2010-11-09 Реагенты и способы для определения клеток ii типа при pnh RU2012124090A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28089709P 2009-11-09 2009-11-09
US61/280,897 2009-11-09
PCT/US2010/055997 WO2011057250A1 (en) 2009-11-09 2010-11-09 Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders

Publications (1)

Publication Number Publication Date
RU2012124090A true RU2012124090A (ru) 2013-12-20

Family

ID=43970419

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012124090/15A RU2012124090A (ru) 2009-11-09 2010-11-09 Реагенты и способы для определения клеток ii типа при pnh

Country Status (15)

Country Link
US (4) US20130045192A1 (OSRAM)
EP (1) EP2499494B1 (OSRAM)
JP (1) JP5635617B2 (OSRAM)
KR (1) KR20120107464A (OSRAM)
CN (1) CN102753976B (OSRAM)
AU (1) AU2010314844B2 (OSRAM)
BR (1) BR112012010985A2 (OSRAM)
CA (1) CA2780153A1 (OSRAM)
ES (1) ES2625470T3 (OSRAM)
IL (1) IL219634A0 (OSRAM)
IN (1) IN2012DN04412A (OSRAM)
MX (1) MX2012005388A (OSRAM)
NZ (1) NZ599813A (OSRAM)
RU (1) RU2012124090A (OSRAM)
WO (1) WO2011057250A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599813A (en) 2009-11-09 2014-07-25 Alexion Pharma Inc Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
US11845779B2 (en) * 2020-10-28 2023-12-19 Ecole Polytechnique Federale De Lausanne (Epfl) Mutant aerolysin and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5106741A (en) 1985-12-20 1992-04-21 The Upjohn Company Tissue plasminogen activator (TPA) analogs
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
AU2326199A (en) 1998-01-20 1999-08-02 Johns Hopkins University, The Detection of gpi anchored proteins
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
CN2648437Y (zh) * 2001-02-13 2004-10-13 中国科学院昆明动物研究所 阵发性睡眠性血红蛋白尿症诊断试剂盒
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7282476B2 (en) * 2001-08-24 2007-10-16 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
NZ599813A (en) 2009-11-09 2014-07-25 Alexion Pharma Inc Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders

Also Published As

Publication number Publication date
CN102753976A (zh) 2012-10-24
AU2010314844B2 (en) 2015-03-12
US11112402B2 (en) 2021-09-07
CA2780153A1 (en) 2011-05-12
US20170285013A1 (en) 2017-10-05
AU2010314844A1 (en) 2012-05-31
JP5635617B2 (ja) 2014-12-03
WO2011057250A1 (en) 2011-05-12
EP2499494B1 (en) 2017-03-08
CN102753976B (zh) 2015-05-06
MX2012005388A (es) 2012-07-23
IL219634A0 (en) 2012-07-31
NZ599813A (en) 2014-07-25
US10126293B2 (en) 2018-11-13
ES2625470T3 (es) 2017-07-19
EP2499494A1 (en) 2012-09-19
US20140286962A1 (en) 2014-09-25
US20190025293A1 (en) 2019-01-24
US20130045192A1 (en) 2013-02-21
IN2012DN04412A (OSRAM) 2015-08-07
KR20120107464A (ko) 2012-10-02
BR112012010985A2 (pt) 2016-11-29
EP2499494A4 (en) 2013-07-10
JP2013510325A (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
Curtis et al. Blood group A and B antigens are strongly expressed on platelets of some individuals
Rebulla A mini-review on platelet refractoriness
Levi review Current understanding of disseminated intravascular coagulation.
Mukhina et al. Multilineage glycosylphosphatidylinositol anchor‐deficient haematopoiesis in untreated aplastic anaemia
RU2012124090A (ru) Реагенты и способы для определения клеток ii типа при pnh
Helley et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
Jackman et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants
Bao et al. Immune regulation in chronically transfused allo‐antibody responder and nonresponder patients with sickle cell disease and β‐thalassemia major
Carden et al. Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia
Euler et al. Xenotransfusion of anemic cats with blood compatibility issues: pre‐and posttransfusion laboratory diagnostic and crossmatching studies
Apelseth et al. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods
Haubelt et al. Effects of solvent/detergent‐treated plasma and fresh‐frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open‐heart surgery
Garcia et al. Sickle cell anemia patients display an intricate cellular and serum biomarker network highlighted by TCD4+ CD69+ lymphocytes, IL‐17/MIP‐1β, IL‐12/VEGF, and IL‐10/IP‐10 Axis
Dijkstra‐Tiekstra et al. Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters
Faget et al. Efficient and specific Ly6G+ cell depletion: A change in the current practices toward more relevant functional analyses of neutrophils
Daltro et al. CD4+ T cell profile and activation response in sickle cell disease patients with osteonecrosis
Chuliber et al. Acquired factor XIII deficiency in patients under therapeutic plasma exchange: a poorly explored etiology
O'Shea et al. Comparison of platelet counting technologies in equine platelet concentrates
Shiue et al. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD 4+ Foxp3+ CD 25− T cells in patients with leukemic cutaneous T‐cell lymphoma
Raife et al. New Aspectsinthe Pathogenesisand Treatmentof Thrombotic Thrombocytopenic Purpuraand Hemolytic Uremic Syndrome
Fuchizaki et al. A novel quantitative method to evaluate the contribution of platelet products to white thrombus formation in reconstituted blood under flow conditions
Petrequin et al. Expression of specific granule markers on the cell surface of neutrophil cytoplasts
Navenot et al. Expression of Glycosyl-Phosphatidylinositol-Linked Glycoproteins in Blood Cells from Paroxysmal Nocturnal Haemoglobinuria Patients a Flow Cytometry Study using CD55, CD58 and CD59 Monoclonal Antibodies
BERKSOY HAYTA et al. Blood mean platelet volume may be predictive for disease course in the cases with pemphigus vulgaris.
Norris et al. Long‐term in vitro reactivity for human leukocyte antigen antibodies and comparison of detection using serum versus plasma

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20160111